Home/Publication/HighLight Capital & Qiming Boost Biologics Platform
HighLight Capital & Qiming Boost Biologics Platform 

04 Jun 2025

US$ 20.00

HighLight Capital has joined Qiming Venture Partners (Qiming), an existing investor of LongBio Pharma (Suzhou) Co ......

Price / article: US$20.00
OR existing subscriber
Related Publications
Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.